Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Poznan, Poland - 5 October 2024: GSK -Glaxosmithkline headquarters office building in Poznan.

Approvals

GSK’s Blenrep Makes Comeback With FDA Nod for Third-Line Multiple Myeloma

The antibody-drug conjugate, withdrawn from the market by GSK in 2022 after failing a confirmatory study, was approved Thursday by the FDA for previously treated patients with multiple myeloma. This is despite a negative advisory committee vote in July.

October 24, 2025

2 min read

Tristan Manalac

Earnings

MASH, Metsera Deals Send Analysts Marauding to Viking

Viking Therapeutics CEO Brian Lian is watching the growth of interest in MASH and obesity but prepared to go it alone.

October 23, 2025

6 min read

Annalee Armstrong

Earnings

‘We’re Not Done’: Roche Plans To Sustain Dealmaking Pace After 89bio

Roche has already signed several high-ticket deals this year, including the $3.5 billion acquisition of 89bio and Genentech’s $2.1 billion molecular glue pact with Orionis Biosciences.

October 23, 2025

2 min read

Tristan Manalac

IN PARTNERSHIP WITH ELEMENT

How Supply Chain Turbulence Is Reshaping Biotech Strategy

In this episode presented by Element Materials Technology, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney discuss how small biotechs face mounting pressure amid manufacturing uncertainties.

October 23, 2025

1 min read

BioSpace Insights

Business and financial crisis vector concept with businessman falling down the hole. Symbol of market crash, recession, risk, bankruptcy and loss. Eps10 illustration.

Cystic fibrosis

Arcturus Plunges on ‘Mixed’ Cystic Fibrosis Data for Inhaled mRNA Drug

Despite showing no meaningful benefit on lung function, Arcturus’ mRNA therapy ARCT-032 reduced mucus volume in patients with cystic fibrosis—an outcome William Blair found “potentially promising.”

October 23, 2025

2 min read

Tristan Manalac

Creative sketch collage of business people handshake gesture approval project development success colleagues cooperation support.

Mergers & acquisitions

Alkermes’ up to $2.1B Purchase of Avadel Sets Groundwork for ‘Strategic Evolution’

With Avadel under its fold, Alkermes expects to accelerate its expansion into the sleep market, laying the foundation for its late-stage narcolepsy asset alixorexton.

October 23, 2025

2 min read

Tristan Manalac

Pictured: Facade of Moderna's building in Massachusetts

Vaccines

Moderna Scraps CMV Vaccine After Phase III Fail

A key question for investors going forward will be whether Moderna’s other latent virus vaccines for Epstein-Barr and shingles can succeed after the failure of the CMV program.

October 23, 2025

3 min read

Tristan Manalac

Illustration of two businessmen with one person’s silhouette showing a Pinocchio nose, signaling dishonesty

Job Trends

Posers and Pretenders: Interview Fraud Rising, Experts Say

Biopharma professionals have become increasingly likely to be dishonest when interviewing for jobs, based on BioSpace interviews with three talent acquisition experts. The experts discuss the reasons why as well as the types of fraud happening, including people posing as applicants.

October 23, 2025

5 min read

Angela Gabriel